Samsung Bioepis agrees on ‘SB5’ patent conflict with AbbVie

Published: 2018-04-10 16:26:00
Updated: 2018-04-10 10:29:15

Samsung Bioepis(CEO/President Han-Seung Ko) agreed on the patent conflict about SB5(generic name: adalimumab, biosimilar referencing Humira), a biosimilar for the treatment of autoimmune disease(Anti-TNF-α).

Samsung Bioepis announced the company signed a license agreement with AbbVie, the origin...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email:

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.